Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: In vitro and in vivo studies

被引:36
作者
Charoo, NA [1 ]
Kohli, K
Ali, A
Anwer, A
机构
[1] Hamdard Univ, Fac Pharm, Dept Pharmaceut, New Delhi 110062, India
[2] Hamdard Univ, Fac Pharm, Dept Pharmacol, New Delhi 110062, India
关键词
ciprofloxacin hydrochloride; bacterial conjunctivitis; ocular inserts;
D O I
10.1081/DDC-120016729
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Reservoir-type ocular inserts were fabricated using sodium alginate containing ciprofloxacin hydrochloride as the core (drug reservoir) that was sandwiched between the Eudragit and/or polyvinylacetate films. Ocular inserts were packaged in aluminium foil and sterilized by gamma radiation. These were tested for sterility as per British Pharmacopoeia (BP). Ocular inserts were evaluated for in vitro release rate studies, microbial efficacy, in vivo release studies, efficacy against induced bacterial conjunctivitis in rabbit's eyes, concentration in the aqueous humor, and stability studies as per the International Conference on Harmonization (ICH) guidelines. Ocular inserts passed the test for sterility. They showed zero-order release of the drug in the in vitro and in vivo release studies over a period of 120 hr. The drug was found to be active against selected microorganisms as was proved by microbial efficacy studies. A high correlation coefficient was found between in vitro and in vivo release rate studies. Better improvement was observed in artificially induced bacterial conjunctivitis in rabbit's eyes, compared with marketed eye drops and placebo. Drug concentration in the aqueous humor was found above Minimum Inhibitory Concentration (MIC-90) against selected microorganisms. Shelf-life of the product was found to be more than 2 years.
引用
收藏
页码:215 / 221
页数:7
相关论文
共 10 条
[1]  
Ali A., 1992, INDIAN DRUGS, V29, P157
[2]  
CHIEN YW, 1995, ENCY PHARM TECHNOLOG, V3
[3]  
Hu FR, 1998, OPHTHALMOLOGY, V105, P269
[4]  
Kamath U. Roopa, 1993, Indian Journal of Pharmaceutical Sciences, V55, P148
[5]  
KEYSERLINGK I, 1997, INT J CLIN PHARM TH, V534, P251
[6]   Formulation and in vivo evaluation of ocular insert containing phenylephrine and tropicamide [J].
Lee, YC ;
Millard, JW ;
Negvesky, GJ ;
Butrus, SI ;
Yalkowsky, SH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 182 (01) :121-126
[7]  
OSMAN C, 1998, CA J OPHTHALMOL, V33, P373
[8]  
PAULINE M, 1996, J PHARM BIOMED ANAL, V14, P641
[9]   OPHTHALMIC DRUG DELIVERY SYSTEMS [J].
SHELL, JW .
SURVEY OF OPHTHALMOLOGY, 1984, 29 (02) :117-128
[10]  
TSAI AC, 1995, J FORMOS MED ASSOC, V94, P760